Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

CONCLUSIONS: Radionecrosis is a significant toxicity in longer-term melanoma survivors with MBM treated with anti-PD-1 and radiotherapy. Identification of those at risk of radionecrosis who may avoid radiotherapy is required.
SIGNIFICANCE: Many patients with melanoma brain metastases receive radiotherapy and anti-PD-1 therapy, and this study demonstrates that approximately one fifth of those who survive beyond one year develop radionecrosis, which causes symptoms that can be difficult to manage. Recent data demonstrate high activity of anti-PD-1-based therapy in patients with brain metastases, such that some patients may be spared radiotherapy and the risk of radionecrosis. This article is protected by copyright. All rights reserved.
PMID: 30767428 [PubMed - as supplied by publisher]

Source: Pigment Cell and Melanoma Research - February 15, 2019 Category: Cytology Authors: Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SM, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong Tags: Pigment Cell Melanoma Res Source Type: research